Phase II trial of sunitinib (Sutent, SU11248) maintenance therapy after induction platinum-based chemotherapy [cisplatin, carboplatin, etoposide, irinotecan] in patients with extensive-stage small cell lung cancer.
Phase of Trial: Phase II
Latest Information Update: 15 Jan 2019
At a glance
- Drugs Sunitinib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 20 Jan 2010 Planned end date changed from 1 Jun 2011 to 1 Jun 2015 as reported by ClinicalTrials.gov.
- 25 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 17 Mar 2008 New trial record.